longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Vapotherm

VAPO

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -0.25, within the reasonable range, cheaper than 69.46% of the time in the past 5 years, and the industry ranks 67/174, the industry Median -0.78.

-0.249xP/E
--Stock price
-0.249xP/E
Stock price--

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.25x
Typical range
-0.49x–-0.23x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
012243648

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BAXUSBaxter
-11.42x141.71%$12.14B
GKOSUSGlaukos
-49.73x75.37%$9.35B
TFXUSTeleflex
-5.19x118.39%$5.35B
IRTCUSIRhythm
-269.95x71.96%$3.77B
PLSEUSPulse Biosciences
-45.34x27.55%$3.63B
AXGNUSAxogen
-74.22x30.15%$2.49B
BFLYUSButterfly Network
-32.37x34.41%$2.42B
ASSTUSStrive
-2.08x63.23%$2.03B
NVCRUSNovocure
-12.53x2.52%$1.86B
KMTSUSKestra Medical Tech
-11.13x0.94%$1.67B
ATECUSAlphatec
-14.56x41.67%$1.60B
DRTSUSAlpha Tau Medical
-15.15x--$1.40B
IARTUSIntegra LifeSciences
-178.82x109.50%$1.30B
TNDMUSTandem Diabetes
-18.21x77.75%$1.15B
AORTUSArtivion
-349.28x266.67%$1.11B
ENOVUSEnovis
-0.97x100.97%$1.06B
PRCTUSPROCEPT BioRobotics
-9.51x3.47%$1.04B
BBNXUSBeta Bionics
-14.00x13.22%$1.02B
CBLLUSCeribell
-14.46x35.15%$954.08M
SIBNUSSI-BONE
-58.66x8.85%$858.28M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.